Report Sections

See All Reports

  • myeloid-derived suppressor cells
  • COVID-19 (39) SARS-CoV-2 (39) vaccine (18) Vaccine (14) Safety (11) Coronavirus (10) Immunogenicity (9) SARS-CoV-2 Vaccine (7) Virus Diseases (6) Ad5 (5) COVID-19 Vaccine (5) COVID-19 vaccine (5) vector vaccine (5) BCG (4) Coronavirus Disease 2019 (4) Covid19 (4) coronavirus (4) COVID (3) COVID 19 (3) Coronavirus infection (3) Covid-19 (3) Dose-escalation (3) Messenger RNA (3) Moderna (3) Protection against COVID-19 (3) RNA Vaccine (3) Recombinant vaccine (3) SARS (3) adenoviral vector (3) mRNA-1273 (3) mRNA-1273 vaccine (3) Ad5-nCoV (2) Adenovirus Vector (2) BCG vaccine (2) COVID-19 Prevention (2) COVID19 (2) ChAdOx1 nCov19 (2) Convalescent plasma (2) DNA vaccine (2) Electroporation (2) Health care workers (2) Immunogencity (2) Passive immunization (2) Prevention (2) Reactogenicity (2) SARS-CoV 2 (2) SARS-CoV-2 infection (2) Severe acute respiratory syndrome coronavirus 2 (2) Sputnik V (2) Tolerability (2) Transfusion (2) covid-19 (2) immunogenicity (2) infectious respiratory diseases (2) novel coronavirus (2) sars-cov-2 (2) 2019 novel coronavirus (1) 2019-nCoV (1) 2019-nCoV (mRNA-1273) (1) ACE2 (1) ARDS (1) AT1 (1) AZD1222 vaccine (1) AZD1222 vaccine for COVID-19 Prevention (1) Ad26 (1) Ad26COVS1 (1) Adenovirus V (1) AlloStim (1) Alvelestat (1) Antibodies, Neutralizing (1) Antibodies, viral/blood (1) Antibody (1) BACILLUS CALMETTE-GUÉRIN VACCINATION (1) BBV152 (1) BCG Vaccination (1) BCG Vaccine (1) Bacille Calmette-Guérin (1) Bacillus Calmette-Guerin (1) Bacillus Calmette-Guérin vaccination (1) Blinded (1) CEPI (1) COVID 19 Vaccine (1) COVID 19 Vaccine Arcturus (1) COVID 2019 (1) COVID-1 (1) COVID-19 infection (1) COVID-19 serotherapy (1) COVID-19, Convalescent plasma therapy (1) COVID-19, SARS-CoV-2 Vaccine (1) COVID-19, Vaccine (1) COVID-2019 (1) COVID19 ( Corona Virus Disease -2019) (1) Clinical trials (1) Coronavirus Infection (1) Coronavirus Infections / therapy (1) Coronavirus Virus Diseases (1) Covid 19 (1) Covid-19 CTL (1) Covid19 Vaccine (1) Covigenix VAX-001 (1) Critically ill COVID-19 patients (1) EGF (1) Endosomal toll-like receptor 3 (1) EpiVacCorona (1) Fibrosis secondary to Covid19 infection (1) Gamaleya (1) Health Workers (1) Healthcare workers (1) Healthy (1) Herpes Zoster (1) Heterologous effects (1) Heterologous prime-boost vaccination (1) Human (1) IFN type1 (1) IFNγ enzyme-linked immune absorbent spot (ELISpot) (1) IN01 vaccine (1) INO-4800 (1) Immunemo (1) Immunemodulation (1) Immunization, Passive (1) Immunoglobulin (1) Immunoglobulin fragments (1) Immunologic Factors (1) Immunology (1) Inactivated SARS-CoV-2 Vaccine (1) Inactivated vaccine (1) Inactive Vaccine (1) Infectiology (1) Infection (1) Innate immune training (1) Interferon Gamma (1) Intranasal Vaccine (1) Intravenous Immunoglobulin (IVIG) (1) Isotretinoin (1) LV-DC vaccine (1) Lentiviral vector (1) Lentiviral vector, Covid-19/aAPC vaccine (1) M-M-R II ® (1) MMR vaccine (1) MMR vaccine, Respiratory failure, (1) MVA (1) Non-specific effects of BCG (1) Pandemics (1) Passive Immunization (1) Phase I (1) Pooled convalescent Plasma (1) QazCovid-in®, vaccine, III phase, efficiency, safety, immunogenicity (1) RNA COVID 19 (1) Randomized controlled (1) Recombinant Novel Coronavirus Vaccine (1) Respiratory disease (1) Retrospective Studies (1) SARS (Severe Acute Respiratory Syndrome) (1) SARS CoV 2 (1) SARS-COV-2 (1) SARS-CoV Infection (1) SARS-CoV-2 (Severe Acute respiratory syndrome Coronavirus 2) (1) SARS-CoV-2-specific serum neutralising antibody titer (1) SARS-CoV-2-surrogate viral neutralising antibody (1) SARS-Cov2 spike protein-binding IgG antibody titer (1) SARS-Cov2 spike protein-specific CD4+ and CD8+ T-cells responses (1) SARS-Cov2 spike protein-specific Th1/Th2 polarisation (1) Sars-Cov-2 Virus Infection (1) Sepsis (1) Severe Acute Respiratory Syndrome (SARS) (1) Severe COVID-19 patients (1) Sputnik (1) Systems Biology (1) T Cells (1) Therapeutic Vaccine (1) Transmission (1) VLA2001 (1) VXA-C0V2-1 (1) Vaccination (1) Vaccinology (1) Vaxart oral vaccine (1) adaptive design (1) adenoviral vector vaccine (1) adenovirus vector (1) adjuvant (1) adult (1) allergy and immunology (1) anti-infective (1) clinical trial (1) corona virus infection (1) coronavirus disease 2019 (1) dendritic cell (1) dose-finding (1) efficacy (1) exploratory efficacy (1) healthy adults (1) healthy elderlies (1) healthy volunteer (1) inactivated vaccine (1) inactivated-adjuvanted Sars-Cov-2 virus vaccine (1) infection (1) inflammation (1) intravenous immunogloulin therapy (1) live attenuated (1) live attenuated vaccine (1) lung disease (1) myeloid-derived suppressor cells (1) novel lipid nanoparticles (LNPs)-encapsulated mRNA-based vaccine (1) off-target effects (1) pandemic (1) passive immunization (1) pneumonia (1) preemptive (1) prevention (1) prophylaxis (1) rAd26-S (1) reactivity (1) respiratory disease (1) safety (1) self amplifying RNA vaccine (1) tablet vaccine (1) therapeutic vaccine (1) tolerability (1) trained immunity (1) trained innate immunity (1) vaccination (1) vaccine, I/II phase, safety, immunogenicity, QazCovid-in® (1) vector (1)

    myeloid-derived suppressor cells

    This report considers only clinical trials that are associated with COVID-19 vaccines.

    Developed by Shray Alag, The Harker School
    Sections: Correlations, Clinical Trials, and HPO

    Correlations computed by analyzing all clinical trials.

    Navigate: Clinical Trials and HPO


    Correlated Drug Terms (3)


    Name (Synonyms) Correlation
    drug1921 MMR vaccine Wiki 1.00
    drug1642 Inactivated SARS-CoV-2 Vaccine (Vero cell) Wiki 0.58
    drug2490 Placebo Wiki 0.13

    Correlated MeSH Terms (3)


    Name (Synonyms) Correlation
    D018746 Systemic Inflammatory Response Syndrome NIH 1.00
    D014115 Toxemia NIH 1.00
    D018805 Sepsis NIH 1.00

    Correlated HPO Terms (1)


    Name (Synonyms) Correlation
    HP:0100806 Sepsis HPO 1.00

    Clinical Trials

    Navigate: Correlations   HPO

    There is one clinical trial.


    1 Use of a Live Attenuated Vaccine Repurposed as an Innate Immune-based Preventive Against COVID-19-associated Sepsis/Inflammation

    The objective of this randomized clinical trial is to test whether administration of live attenuated MMR vaccine (measles mumps rubella; Merck) to eligible adults at highest risk for contracting COVID-19 (healthcare workers, first responders), can induce non-specific trained innate immune leukocytes that can prevent/dampen pathological inflammation and sepsis associated with COVID-19-infection, if exposed.

    NCT04475081
    Conditions
    1. Sepsis Syndrome
    Interventions
    1. Biological: MMR vaccine
    MeSH:Sepsis Toxemia Systemic Inflammatory Response Syndrome
    HPO:Sepsis

    Primary Outcomes

    Description: peripheral blood monocytic MDSCs (M-MDSC) and/or granulocytic MDSCs (G-MDSC) determined by flow cytometry from whole blood samples as percentage/fold increase over baseline

    Measure: Induction of myeloid-derived suppressor cells (MDSCs)

    Time: 14 days post-vaccination

    Description: peripheral blood monocytic MDSCs (M-MDSC) and/or granulocytic MDSCs (G-MDSC) determined by flow cytometry from whole blood samples as percentage/fold increase over baseline

    Measure: Induction of MDSCs

    Time: 30 days post vaccination

    Description: peripheral blood monocytic MDSCs (M-MDSC) and/or granulocytic MDSCs (G-MDSC) determined by flow cytometry from whole blood samples as percentage/fold increase over baseline

    Measure: Induction of MDSCs

    Time: 60 days post vaccination

    Description: peripheral blood monocytic MDSCs (M-MDSC) and/or granulocytic MDSCs (G-MDSC) determined by flow cytometry from whole blood samples as percentage/fold increase over baseline

    Measure: Induction of MDSCs

    Time: 12 months post vaccination

    Secondary Outcomes

    Description: COVID-19 antibodies (seropositive) or COVID-19 RNA+ as evidence of infection

    Measure: COVID-19 infection positive

    Time: 14 days post-vaccination

    Description: COVID-19 antibodies (seropositive) or COVID-19 RNA+ as evidence of infection

    Measure: COVID-19 infection positive

    Time: 30 days post-vaccination

    Description: COVID-19 antibodies (seropositive) or COVID-19 RNA+ as evidence of infection

    Measure: COVID-19 infection positive

    Time: 60 days post-vaccination

    Description: COVID-19 antibodies (seropositive) or COVID-19 RNA+ as evidence of infection

    Measure: COVID-19 infection positive

    Time: 12 months post-vaccination

    Description: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)

    Measure: Health questionnaire

    Time: 14 days post-vaccination

    Description: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)

    Measure: Health questionnaire

    Time: 30 days post-vaccination

    Description: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)

    Measure: Health questionnaire

    Time: 60 days post-vaccination

    Description: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)

    Measure: Health questionnaire

    Time: 3 months post-vaccination

    Description: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)

    Measure: Health questionnaire

    Time: 4 months post-vaccination

    Description: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)

    Measure: Health questionnaire

    Time: 5 months post-vaccination

    Description: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)

    Measure: Health questionnaire

    Time: 6 months post-vaccination

    Description: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)

    Measure: Health questionnaire

    Time: 7 months post-vaccination

    Description: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)

    Measure: Health questionnaire

    Time: 8 months post-vaccination

    Description: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)

    Measure: Health questionnaire

    Time: 9 months post-vaccination

    Description: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)

    Measure: Health questionnaire

    Time: 10 months post-vaccination

    Description: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)

    Measure: Health questionnaire

    Time: 11 months post-vaccination

    Description: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)

    Measure: Health questionnaire

    Time: 12 months post-vaccination

    Related HPO nodes (Using clinical trials)


    Reports

    Data processed on January 01, 2021.

    An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

    Drug Reports   MeSH Reports   HPO Reports  

    Interventions

    4,818 reports on interventions/drugs

    MeSH

    706 reports on MeSH terms

    HPO

    306 reports on HPO terms

    All Terms

    Alphabetical index of all Terms

    Google Colab

    Python example via Google Colab Notebook